Camporesi Enrico, Vezzani Giuliano, Zanon Vincenzo, Manelli Daniele, Enten Garrett, Quartesan Silvia, Bosco Gerardo
Emeritus Professor of Surgery /Anesthesiology and Molecular Pharmacology / Physiology and TeamHealth Anesthesia Research Institute, University of South Florida, Tampa, Florida.
Biomedical Sciences, Universita degli Studi di Padova, Padova, Italy.
Undersea Hyperb Med. 2017 Nov-Dec;44(6):497-508. doi: 10.22462/11.12.2017.1.
Femoral head necrosis (FHN) is a common invalidating disease with an unclear etiology and pathophysiology that affects middle-aged people. FHN may lead to joint collapse and require invasive treatments. Because of its clinical and socioeconomic significance, an early diagnosis, staging and appropriate treatment are required. Unfortunately, to date a unique algorithm for the treatment of FHN has not been defined.
In this report we summarize the Tenth European Consensus Conference on hyperbaric medicine (April 2016, France), during which experts from Europe revised the list of accepted indications for hyperbaric oxygen (HBO₂) treatment, including FHN.
In this report all aspects of osteonecrosis discussed during the meeting have been considered: pathophysiology,clinical presentation, standard management, HBO₂ therapy and evidence-based review of its efficacy. All observations are based on a thorough review of the best available research and evidence-based medicine.
The Consensus Conference in Lille established FHN as an indication for HBO₂ therapy and suggested a protocols guideline to adopt for this pathology.
股骨头坏死（FHN）是一种常见的致残性疾病，病因和病理生理学尚不明确，主要影响中年人。FHN可能导致关节塌陷，需要进行侵入性治疗。鉴于其临床和社会经济意义，需要早期诊断、分期并采取适当治疗。不幸的是，迄今为止尚未确定一种独特的FHN治疗算法。
在本报告中，我们总结了第十届欧洲高压氧医学共识会议（2016年4月，法国），期间欧洲专家修订了包括FHN在内的高压氧（HBO₂）治疗公认适应症清单。
本报告考虑了会议期间讨论的骨坏死的各个方面：病理生理学、临床表现、标准管理、HBO₂治疗及其疗效的循证综述。所有观察结果均基于对现有最佳研究和循证医学的全面回顾。
里尔的共识会议将FHN确定为HBO₂治疗的适应症，并建议针对该病理情况采用的方案指南。
